Status: Not yet recruiting
Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
This study is an open label, single arm exploratory clinical trial of IC19 CAR-T cell therapy for refractory systemic lupus erythematosus. Patients who are still in an active state after systemic treatment using the standard treatment regimen specified in the treatment guidelines were selected to receive IC19 CAR-T cell single pulse infusion therapy.
Participants needed: 6
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.Updated: Mar 24, 2025
Eligibility criteria
Subjects diagnosed with systemic lupus erythematosus who meet the 2019 European... [+9]
Diseases of the central nervous system that have clinical significance in the pa... [+19]